ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease
WESTON, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq:ZVSA or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that world renowned inflammasome researchers and inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100 have published a scientific paper in the peer-reviewed journal, Alzheimer’s & Dementia: Translational Research & Clinical Interventions.
Related news for (ZVSA)
- ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
- 24/7 Market News Snapshot 08 July, 2025 – ZyVersa Therapeutics, Inc. Common Stock (NASDAQ:ZVSA)
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/08/25 11:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/08/25 08:00 AM
- ZyVersa Backs FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in Patient with ApoCII Amyloidosis